Exact Mass: 415.187137
Exact Mass Matches: 415.187137
Found 122 metabolites which its exact mass value is equals to given mass value 415.187137,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Naltriben
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
Mavelertinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Rupatadine
C26H26ClN3 (415.18151460000007)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Rupatadine is a second-generation tricyclic H1-antihistamine.
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
CID 9844747
C22H26FN3O4 (415.19072480000005)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects[1][2][3].
(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-(4-hydroxyphenyl)Propanoic acid
Gly Gly Pro Trp
Gly Gly Trp Pro
Gly Pro Gly Trp
Gly Pro Trp Gly
Gly Trp Gly Pro
Gly Trp Pro Gly
Pro Gly Gly Trp
Pro Gly Trp Gly
Pro Trp Gly Gly
Trp Gly Gly Pro
Trp Gly Pro Gly
Trp Pro Gly Gly
Donepezil Hydrochloride
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors
Benzeneethanol, 4-[1-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1-methylethyl]-, 4-methylbenzenesulfonate (ester)
C23H29NO4S (415.1817194000001)
(S)-3-(4-ACETYLPHENYL)-4-ISOPROPYLOXAZOLIDIN-2-ONE
Coelenterazine cp
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-phenyl-N-(3-pyridinylmethyl)- (9CI)
methyl 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)ethylidene]-1,3,3-trimethylindoline-5-carboxylate
3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF[1][2].
1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Maleate
C23H29NO4S (415.1817194000001)
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine
1-(phenylmethyl)-N-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinecarbohydrazide
C22H29N3O3S (415.1929524000001)
(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
C21H23F2N5O2 (415.18197219999996)
(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
C21H23F2N5O2 (415.18197219999996)
Rupatadine
C26H26ClN3 (415.18151460000007)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
N-[4-(4-methylphenoxy)phenyl]-2-[2-(2-oxopyrrolidin-1-yl)anilino]acetamide
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
(10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione
6-phenyl-N-[(3-phenylphenyl)methyl]-3-(2-pyridinyl)-1,2,4-triazin-5-amine
(3S,3aR,8aS,8bS)-5-ethyl-2-(phenylmethyl)spiro[1H-indole-3,4-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1,2,3-trione
1-acetyl-N-[3-(N-ethyl-3-methylanilino)propyl]-2,3-dihydroindole-5-sulfonamide
C22H29N3O3S (415.1929524000001)
1-(4-tert-butylphenyl)sulfonyl-N-(2-pyridinylmethyl)-2-piperidinecarboxamide
C22H29N3O3S (415.1929524000001)
5-(Pentoxymethyl)-3-[(2E)-2-[(4-phenyl-1,3-thiazol-2-yl)hydrazinylidene]propyl]oxolan-2-one
C22H29N3O3S (415.1929524000001)
[2-(2,5-dimethylanilino)-2-oxoethyl] (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoate
1-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]ethanone
2-[(2R,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2S,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
[(1R,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
4-[4-[(2S,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
4-[4-[(2R,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
2-[(2R,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2S,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2S,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2R,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2R,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-[(2S,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
C22H26FN3O4 (415.19072480000005)
[(1R,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-pyridin-4-ylmethanone
4-[4-[(2S,3S)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
ALM301
ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 μM, 0.09 μM and 2.75 μM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].
3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2s,10s,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2s,10s,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[1-(hydroxymethyl)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-5-yl]oxy}oxane-3,4,5-triol
C19H29NO9 (415.18422240000007)